What's That Drug Called?
Executive Summary
The trade name of Alnara Pharmaceuticals' liprotamase for exocrine pancreatic insufficiency has suffered a fate in many ways similar to what happened to the application itself at the advisory committee: it's been knocked around a bit by FDA and others.
You may also be interested in...
Lilly To Buy Alnara And Its Non-Porcine Pancreatic Enzyme Replacement Therapy
Alnara hopes to leverage Lilly's prior success with recombinant insulin products.
Pancreatic Enzyme Product Activity Steps Up As NDA Deadline Approaches
With the NDA submission deadline for previously unregulated pancreatic enzyme products less than a year away, the exocrine pancreatic insufficiency market is heating up as manufacturers of pig-derived products seek to stay on the market and a non-porcine alternative noses closer to submission
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.